Home Cart Sign in  
Chemical Structure| 728-61-0 Chemical Structure| 728-61-0

Structure of Linderalactone
CAS No.: 728-61-0

Chemical Structure| 728-61-0

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Linderalactone, a natural product isolated and purified from the roots of Lindera aggregata, shows significant inhibitory effects on superoxide anion generation by human neutrophils in response to fMLP/CB, values of IC50 is 8.48 µg/mL.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Linderalactone

CAS No. :728-61-0
Formula : C15H16O3
M.W : 244.29
SMILES Code : O=C1C2=C[C@@](C3=C(OC=C3C)C/C(C)=C/CC2)([H])O1
MDL No. :MFCD12031632
InChI Key :LWCKQMHMTSRRAA-QGQQYVBWSA-N
Pubchem ID :6450191

Safety of Linderalactone

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P280-P301+P312-P302+P352-P305+P351+P338

Related Pathways of Linderalactone

GPCR

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
SW-1990 0, 30, 40, 50, 60, 70, 80, 90, and 100 μM 0, 24, and 48h Linderalactone inhibited pancreatic cancer cell activity in a time- and dose-dependent manner. PMC9371883
CFPAC-1 0, 30, 40, 50, 60, 70, 80, 90, and 100 μM 0, 24, and 48h Linderalactone inhibited pancreatic cancer cell activity in a time- and dose-dependent manner. PMC9371883
BXPC-3 0, 30, 40, 50, 60, 70, 80, 90, and 100 μM 0, 24, and 48h Linderalactone inhibited pancreatic cancer cell activity in a time- and dose-dependent manner. PMC9371883
ASPC-1 0, 30, 40, 50, 60, 70, 80, 90, and 100 μM 0, 24, and 48h Linderalactone inhibited pancreatic cancer cell activity in a time- and dose-dependent manner. PMC9371883
LX-2 cells 10 μM 24 h To evaluate the effect of LIN on fibrogenic gene expression in LX-2 cells, results showed that LIN significantly reduced the expression of ACTA2, VIM, TGF-β, FN1, DES, and COL1A1. PMC9946977

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
BALB/c nude mice Pancreatic cancer xenograft model Intraperitoneal injection 25mg/kg and 50mg/kg Every three days for three weeks Linderalactone inhibited tumor growth without obvious chemical toxicity. PMC9371883
C57BL/6 mice DSS-induced colitis model Oral gavage 0.5, 1, 2 g/kg Once daily for 14 days Improved colitis symptoms, reduced intestinal permeability, modulated Th17/Treg cell balance PMC8170699
C57BL/6 mice CCl4-induced liver fibrosis model Intragastric administration 20 and 40 mg/kg Once daily for 4 weeks To evaluate the therapeutic effect of LIN on CCl4-induced liver fibrosis, results showed that LIN significantly reduced serum AST/ALT levels, liver hydroxyproline content, and collagen deposition, ameliorating liver fibrosis. PMC9946977

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

4.09mL

0.82mL

0.41mL

20.47mL

4.09mL

2.05mL

40.93mL

8.19mL

4.09mL

References

 

Historical Records

Categories